Printer Friendly

Genetic Polymorphisms of IL17 and Chagas Disease in the South and Southeast of Brazil.

1. Introduction

Chagas disease (CD) is a serious anthropozoonosis common in the Americas and found mainly in endemic areas of the 21 Latin American countries [1]. On account of multinational initiatives, infection prevalence is progressively decreasing, and it is estimated that 6 to 8 million individuals are currently infected in the world, with an incidence of 28.000 cases a year [2]. Chagas disease presents an acute phase and a chronic phase. After the acute phase, most of the infected patients enter in the chronic phase of the disease and about 60 to 70% of infected persons are considered to have the indeterminate form (asymptomatic) of the disease [3-6]. After several years (10 to 30) of starting the chronic phase, 30 to 40% of the patients develop clinical manifestations known as the clinical forms: cardiac, digestive (mainly megaesophagus and megacolon), and cardiodigestive [5, 6]. The chronic Chagas cardiomyopathy (CCC) is the most severe form of the disease that affects 20 to 30% of the infected individuals. In endemic areas the disease is the main death cause in patients aged between 30 and 50 years [5, 7].

It is known that genetic variability and immunologic response influence the pathogenesis of the chronic phase of the disease. Associations were observed in several cytokine genes [8] with the susceptibility or protection against the development or progression of the CD and/or its clinical forms. The IL-17 is a proinflammatory cytokine secreted by T cells activated and expressed in different tissues. This cytokine takes part in inflammatory responses mediated by T cells and plays an important role in the tissue homeostasis and diseases progression [9]. The IL-17F presents a high degree of homology with the IL-17A (57% identical) [9] and seems to have a biological action similar to IL-17A, in vitro and in vivo, though significantly weaker [10]. The genes that codify them are mapped in the same chromosome, in the position 6p12 [9,11].

Polymorphism in genes encoding cytokines may influence the level of cytokines production and, consequently, cause different immunological responses to different diseases. Previous studies show that genetic polymorphisms of IL17A G197A and IL17F T7488C affect the production of IL-17A and F, respectively [12, 13]. Such polymorphisms have already been associated with autoimmune and inflammatory diseases, as rheumatoid arthritis [14], periodontitis [15], and cancer, both gastric [16] and breast cancer [17]. To our knowledge, only one study involving the SNPs of IL17A and the CD [18] was found so far, and if we consider the SNPs of IL17F there are no related articles published yet. For this reason, our study aims to investigate whether the genetic polymorphisms of IL17A G197A (rs2275913) and IL17F T7488C (rs763780) were related to CD and/or the severity of the left ventricular systolic dysfunction (LVSD) in patients with CCC from North and Northeast regions of Parana and the Northeast region of Sao Paulo (states located in the South and Southeast of Brazil, resp.).

2. Material and Methods

2.1. Patients and Controls. For this study, 260 patients with chronic CD were selected from different municipalities in the North and Northwest regions of Parana and in the Northwest region of Sao Paulo. The patients were cared for in the Chagas Disease Laboratory in the State University of Maringa, the Clinical Hospital in Londrina, and the Base Hospital of the Medical School in Sao Jose do Rio Preto. All patients were submitted to a resting electrocardiogram (ECG) exam and a two-dimensional echocardiography. Patients who presented a normal ECG were classified as patients without CCC and patients with electrocardiographic changes, common to CCC, were classified as patients with CCC. The severity of the LVSD was measured according to the left ventricular ejection fraction (LVEF) and the Teichhoolz method was applied following the II Brazilian Guideline for Severe Heart Diseases [19]. Patients with CCC were classified considering the (LVEF) in three different groups: patients without LVSD (LVEF > 60%); patients with mild to moderate LVSD (LVEF 40-60%); and patients with severe LVSD (LVEF < 40%). To all statistical analysis were considered the following groups: all Chagas disease patients (CD), chronic Chagas cardiomyopathy patients (CCC), without Chagas cardiomyopathy patients (without CCC), chronic Chagas cardiomyopathy patients with LVSD (with LVSD), chronic Chagas cardiomyopathy patients without LVSD (without LVSD), patients with mild to moderate LVSD (Mild/moderate LVSD), and patients with severe LVSD (severe LVSD).

The control group was composed of 150 individuals, healthy and nonrelated, patient's spouses, and contacts retirement communities' residents with negative serology to T. cruzi antigens. The clinicopathological features of patients and controls are presented in Table 1. No significant differences were observed among groups in terms of gender, but differences in age were observed between CCC and without CCC patients (63.9 [+ or -] 10.2 versus 58.6 [+ or -] 7.8, respectively; P < 0.05). Due to the significant miscegenation of Brazilian population we consider patients and controls as a mixed ethnic group (Caucasians, Mulattos, and Blacks) according to Parra et al. (2003) [20]. Mean age, gender rates, and residence in the same geographical areas were carefully matching to select the groups.

The laboratory diagnosis of CD in patients and controls was made by ELISA (Enzyme-Linked ImmunoSorbent Assay) test, in serum or plasma, using the immunoassay "Chagas" from Abbott Laboratories (Santiago, Chile). In cases of weak reagent, the diagnosis was confirmed by the indirect immunofluorescence test (IIFT) with the iMuNOCRUZI[R] antigen (Biolab, Rio de Janeiro, Brazil) or ELISAcruzi (bioMerieus SA, Brazil), respecting the manufacturer's instructions.

The Ethics committees from each institution have approved this study, as seen in the protocols they have registered (012/2010-COPEP-UEM, CAAE 0296.0.093.000-09; FAMERP--# 009/2011), and written informed consent was obtained from all subjects prior to participation.

2.2. DNA Extraction and Genotyping. The extraction method used in this research was the salting-out adapted [21]. The genomic DNA was extracted from 250 [micro]L of buffy-coat obtained from 5 mL of peripheral blood collected in tubes with EDTA (Ethylenediaminetetraacetic acid). The material's concentration and purity were determined by NanoDrop 2000[R] equipment (Thermo Scientific, Wilmington, USA).

The SNPs in IL-17A (rs2275913) and IL-17F (rs763780) were genotyped using PCR-RFLP (Polymerase Chain Reaction-Restriction Fragment Length Polymorphism) [15]. The primers sequences to IL17A G197A were sense 57-AACAAGTAAGAATGAAAAGAGGACATGGT-3' and antisense 5'-CCCCCAATGAGGTCATAGAAGAATC-3, while to IL17F T7488C they were sense 5,-ACCAAGGCTGCTCTGTTTCT-3' and antisense 5'-GGTAAGGAGTGGCATTTCTA-37. The reaction of DNA amplification was made in a total volume of 30/Th, containing 100 ng of genomic DNA, 1,0 [micro]M from each primer, 200 [micro]M from each dNTP, 2,0 mM of MgCl2, 3 [micro]L of 10 x PCR buffer, and 1,5 U of Taq DNA polymerase (Invitrogen Life Technologies, Grand Island, NY, USA). The PCR products were digested during one hour submitted to 37[degrees]C with the enzyme XagI (Fermentas, Canada) to IL17A G197A and the enzyme NlaIII (New England Biolabs) to IL17F T7488C and, subsequently, separated by agarose gel electrophoresis to 3,5% with SYBR Green (Invitrogen Life Technologies, Grand Island, NY, USA).

2.3. Statistical Analysis. The allele and genotype frequencies of IL17A G197A and IL17F T7488C were estimated and the genotype distribution was evaluated to Hardy-Weinberg balance [22]. The association tests were realized to the codominant, dominant, recessive, overdominant, and log-additive genetic inheritance models. The P [less than or equal to] 0.05 values were considered statistically significant to Chi-square test with Yates correction and logistic regression. The statistical comparisons between these groups were realized and the estimated risk to develop CD and/or CCC in individuals who hold genetic polymorphisms was calculated by determination of OD (Odds Ratio) with 95% of confidence interval, adjusted by gender and age. All statistical analysis was performed using the software SNPStats (http://bioinfo [23] and the OpenEpi program, version 3.03a (

3. Results

The ratio distributions of genotype frequency for all analyzed genes were in Hardy-Weinberg equilibrium (P > 0.05). In order to evaluate the possible association of IL17A G197A and IL17F T7488C SNPs and Chagas disease, the allele and genotype frequencies between patients (CD) and their subgroups (CCC, without CCC, with LVSD, without LVSD, Mild/moderate LVSD, severe LVSD) and controls were compared (Table 2). Statistically significant differences were observed for A allele and A/A genotype of IL17A but no significant difference was found to IL17F.

The A allele frequency of IL17A was significantly higher in the CD patients when compared to controls (P = 0.032, OR = 1.46, 95% CI = 1.05-2.05). The same was found when CCC patients (P = 0.021, OR = 1.52, 95% CI = 1.08-2.15), patients with CCC and LVSD (P = 0.009, OR = 1.73, 95% CI = 1.15-2.59), and patients with CCC and severe LVSD (P = 0.009, OR = 1.97, CI = 1.20-3.21) were compared to controls.

The A/A genotype was more frequent in the CD patients than in the control group and statistically significant differences were observed in more than one model of genetic inheritance (Codominant: P = 0.019, OR = 4.53, 95% CI = 1.31-15.73; Recessive: P = 0.0089, OR = 4.12, 95% CI = 1.20-14.13; Log-additive: P = 0.02, OR = 1.50, 95% CI = 1.06-2.13). Same results can be seen when the subsets are compared: CCC versus controls (Codominant: P = 0.01, OR = 5.16, 95% CI = 1.47-18.14; Recessive: P = 0.0048, OR = 4.67, 95% CI = 1.35-16.18; Log-additive: P = 0.013, OR = 1.57, 95% CI = 1.09-2.24); patients with CCC and LVSD versus controls (Codominant: P = 0.006, OR = 6.81, 95% CI = 1.77-26.29; Dominant: P = 0.034, OR = 1.73, 95% CI = 1.04-2.87; Recessive: P = 0.0045, OR = 5.73, 95% CI = 1.52-21.64; Log-additive: P = 0.0046, OR = 1.85, 95% CI = 1.20-2.85); patients with CCC and severe LVSD versus controls (Codominant: P = 0.0047, OR = 9.64, 95% CI = 2.28-40.85; Recessive: P = 0.002, OR = 8.18, 95% CI = 2.00-33.51; Log-additive: P = 0.057, OR = 2.11, 95% CI = 1.24-3.60). For all comparisons, the recessive inherence model was the best according Akaike information criteria (AIC). It means that two copies of A are necessary to change the risk, so G/A or G/G have the same effect. No difference was observed when allele and genotype frequencies of IL17A were compared between patients with CCC and patients without CCC. Likewise, no association was observed when the progression of cardiac forms was considered: the different forms (without LVSD, with LVSD, mild/moderate LVSD, and severe LVSD) were compared with each other and no statistically significant difference was noticed.

After stratifying according to gender significant differences were observed for IL17A and IL17F genotype frequencies when the progression of cardiac form was evaluated. The IL17A A/A genotype was more frequent in female with LVSD (OR = 6.63, 95% CI = 1.21-36.40) and with mild/moderate LVSD (OR = 7.57, 95% CI = 1.07-53.40) than in the control group, although not significant males with LVSD also had higher frequency of AA genotype compared to controls (13.5 versus 7.84%, resp.) (Table 3). In relation to IL17F, the T/C genotype was more frequent in male patients with severe LVSD when compared to other groups: without LVSD (OR = 4.82, 95% CI = 1.55-14.98), with mild/moderate LVSD (OR = 6.00, 95% CI = 1.18-30.63), without CCC patients (OR = 6.70, 95% CI = 1.19-37.53), and controls (OR = 3.40, 95% CI = 1.24-9.31). In female statistical difference was not observed, although T/C was higher in mild/moderate LVSD (17%) when compared to others patients and control (Table 4). Considering the variable age, no significant difference was observed between IL17 SNPs and CD and/or the severity of the left ventricular systolic dysfunction (LVSD).

4. Discussion

The identification of genes that are candidates for susceptibility or protection against CD has major implications, not only to better understand the pathogenesis of the disease, but also to control and develop therapeutic strategies. In this study, a possible association between the genetic polymorphisms of IL17A G197A and IL17F T7488C with cD and the severity of CCC was investigated in a population from South and Southwest regions in Brazil.

In this study, the IL17A A allele and the A/A genotype were more frequent in CD and CCC patients, female with LVSD or mild/moderate LVSD and male with LVSD when compared to control. The risk to severe LVSD was observed in male carrying the IL17F T/C genotype. The IL17 polymorphism could be correlated to the risk of disease, indicating susceptibility to chronic Chagas disease and increasing risk of severe cardiomyopathy when gender was considered in multivariate analyses. The mutant allele A of IL17A was associated with a higher production of IL-17 [12] and the IL-17F activity is similar to IL-17A, although significantly weaker [10, 12, 13]. Based on these findings, it is possible to infer that the higher production of IL-17, a proinflammatory cytokine, could contribute to tissue damage and might be related to the development and progression of CCC in this population.

Considering the IL-17 biological function in Chagas disease, Guedes et al. [24] showed that the neutralization of IL-17 in mice BALB/c infected with T. cruzi has resulted in a higher recruitment of inflammatory cells to the cardiac tissue in the acute phase of the infection, leading to an increase in myocarditis and, consequently, premature death, despite the reduction of the local parasitism. Miyazaki et al. [25] have reported the importance of the IL-17 in the T. cruzi infection and the cardiac inflammation control in CD. They observed that in the experimental acute infection with T. cruzi, disabled mice in IL-17 presented a higher mortality rate and parasitemia when compared to the group control (C57BL/6, wild type), as well as a lower expression of cytokines, as IFN-[gamma], IL-6, and TNF-[alpha], suggesting a protective role of IL-17 in the acute phase of the disease. The neutralization of IL-17 also resulted in a higher production of IL-12, IFN-[gamma], TNF-[alpha], chemokines, and its receptors, indicating that the IL-17 may perform a role in the control of cardiac inflammation, through the modulation of Th1 response. On the other hand, Magalhaes et al. [26] showed that in Chagas patients with cardiac form the total lymphocytes and the Th17 cells presented a low expression of IL-17A in comparison to the patients with the indeterminate form and control group, and the analysis of correlation between IL-17A and the cardiac function showed that the high expression of this cytokine was associated with a better clinical outcome in the human CD, according to values of the ejection fraction and left ventricular diastolic diameter, indicating a protective role against the severity of CCC.

Five SNPs of IL17A were analyzed in patients with CD in a population of an endemic region of Colombia. >The SNP rs8193036 was associated with the protection against T cruzi infection and the development of CCC. Meanwhile for the SNP rs2275913, the same SNP evaluated in this study, the frequency of allele A was higher in patients than in controls and significant difference was observed, although significance was lost after the correction [18]. We observed that IL17A A allele and AA genotype were higher in Chagas disease as well in CCC with or without LVSD, but no difference was observed between CD or CCC patients. However, after stratifying according to gender, female with IL17A AA genotype had risk of developing mild/moderate LVSD (approximately seven), as male to develop LVSD (although not significant); and male with IL17F T/C genotype had higher risk to develop severe LVSD compared to other cardiac form and controls.

A study conducted by Peng et al. [27] in Chinese patients with dilated cardiomyopathy did not find association with IL17A G197A and IL17F T7488C polymorphism. However, after stratification by gender, the IL17F was associated with dilated cardiomyopathy in male patients that present the T/C-C/C genotypes, suggesting that the presence of the rare allele (C) might be associated with the disease in these patients. In this study we found that the IL17F T/C genotype was associated with developing severe LVSD in male patients when the sample stratification by gender was done.

The risk of development severe cardiac form in male with CD was showed in two Brazilian studies. Rassi et al. [28] showed that gender (male) and left ventricular systolic dysfunction on echocardiography are potential risk factors for death in subjects with CD. They evaluated a cohort of 424 Brazilian outpatients followed for about eight years and confirmed the results in 153 patients of other Brazilian community hospital. Fae et al. [29] observed a higher risk of developing severe forms of cardiomyopathy in men (OR = 8.75), corroborating the results of this study.

The present study has potential limitations. The major limitation was the number of patients limiting the significance of results and consequently no strong association could be found, principally when independent multiple comparisons were carried out. However, the risk of population stratification bias, due to differences in ethnic background, was minimized by matching patients with controls individuals of the same ethnic background. Mean age, gender rates, and residence in the same geographical areas were carefully matching to select the groups. Another limitation was that IL17 gene expression or serum levels were not evaluated.

5. Conclusions

In these South and Southeast Brazilian patients, the IL17A polymorphisms, AA genotype and A allele, were associated with susceptibility to chronic CD and the severity of the left ventricular systolic dysfunction (LVSD). In addition, the IL17A A/A genotype was associated with mild/moderate LVSD in female patients, whereas the IL17F T/C genotype was associated with severe LVSD in male patients. These results suggest the possible involvement of the polymorphisms of IL17A and IL17F in the susceptibility to chronic CD and in development and progression of CCC. Additional studies are needed to confirm these results and for understanding the functional role polymorphism in CD.


Partial data from this study were presented in the 20th Congress of the Brazilian Society of Bone Marrow Transplantation, Fortaleza, Ceara, Brazil, in August 24-27, 2016, available in and identified as P114. The opinions, assumptions, and conclusions or recommendations expressed in this material are the responsibility of the authors and do not necessarily reflect the views of the FAPESP. The present address of Reinaldo Bulgarelli Bestetti is Departamento de Medicina, Universidade de Ribeirao Preto, Av. Costabile Romano, No. 2201, 14096-900 Ribeirao Preto, SP, Brazil.

Competing Interests

The authors declare that there is no conflict of interests involved.


The authors appreciate the participation and cooperation of all volunteers (patients and controls) and of the Regional Blood Bank in Maringa, the Clinical Hospital in Londrina, the Chagas Disease Laboratory in State University of Maringa (UEM), the Base Hospital of Medical School in Sao Jose do Rio Preto, and the technicians of the Immunogenetics Laboratory (LIG-UEM) for the assistance with the sample collection. This study was financially supported by Fundacao Araucaria (State of Parana Research Foundation), CNPq, CAPES, and FAPESP (Sao Paulo Research Foundation) Grants nos. 2011/08075-4, 2013/06580-9, and LIG-UEM.


[1] WHO, "Chagas disease (American trypanosomiasis)--Facts Sheet," in The Weekly Epidemiological Records, vol. 87, pp. 519-522, World Health Organization, Geneva, Switzerland, 2012.

[2] PAHO, Chagas Disease (American Trypanosomiasis), Regional Office for the Americas of the World Healthg Organization, Washington, DC, USA, 2014.

[3] A. Moncayo, "Chagas disease: current epidemiological trends after the interruption of vectorial and transfusional transmission in the southern cone countries," Memorias do Instituto Oswaldo Cruz, vol. 98, no. 5, pp. 577-591, 2003.

[4] A. M. Macedo, C. R. Machado, R. P. Oliveira, and S. D. J. Pena, "Trypanosoma cruzi: genetic structure of populations and relevance of genetic variability to the pathogenesis of chagas disease," Memorias do Instituto Oswaldo Cruz, vol. 99, no. 1, pp. 1-12, 2004.

[5] A. Rassi Jr., A. Rassi, and J. A. Marin-Neto, "Chagas disease," The Lancet, vol. 375, no. 9723, pp. 1388-1402, 2010.

[6] A. Rassi, A. Rassi, and J. Marcondes de Rezende, "American Trypanosomiasis (Chagas Disease)," Infectious Disease Clinics of North America, vol. 26, no. 2, pp. 275-291, 2012.

[7] A. Rassi Jr., A. Rassi, and J. A. Marin-Neto, "Chagas heart disease: pathophysiologic mechanisms, prognostic factors and risk stratification," Memorias do Instituto Oswaldo Cruz, vol. 104, no. 1, pp. 152-158, 2009.

[8] C. M. Ayo, M. M. D. O. Dalalio, J. E. L. Visentainer et al., "Genetic susceptibility to chagas disease: an overview about the infection and about the association between disease and the immune response genes," BioMed Research International, vol. 2013, Article ID 284729, 13 pages, 2013.

[9] T. A. Moseley, D. R. Haudenschild, L. Rose, and A. H. Reddi, "Interleukin-17 family and IL-17 receptors," Cytokine and Growth Factor Reviews, vol. 14, no. 2, pp. 155-174, 2003.

[10] N. Hizawa, M. Kawaguchi, S.-K. Huang, and M. Nishimura, "Role of interleukin-17F in chronic inflammatory and allergic lung disease," Clinical and Experimental Allergy, vol. 36, no. 9, pp. 1109-1114, 2006.

[11] T. Korn, E. Bettelli, M. Oukka, and V. K. Kuchroo, "IL-17 and Th17 cells," Annual Review of Immunology, vol. 27, pp. 485-517, 2009.

[12] J. L. Espinoza, A. Takami, K. Nakata et al., "A genetic variant in the IL-17 promoter is functionally associated with acute graft-versus-host disease after unrelated bone marrow transplantation," PLoS ONE, vol. 6, no. 10, Article ID e26229, 2011.

[13] M. Kawaguchi, D. Takahashi, N. Hizawa et al., "IL-17F sequence variant (His161Arg) is associated with protection against asthma and antagonizes wild-type IL-17F activity," Journal of Allergy and Clinical Immunology, vol. 117, no. 4, pp. 795-801, 2006.

[14] G. B. N. Nordang, M. K. Viken, J. E. Hollis-moffatt et al., "Association analysis of the interleukin 17A gene in Caucasian rheumatoid arthritis patients from Norway and New Zealand," Rheumatology, vol. 48, no. 4, pp. 367-370, 2009.

[15] J. M. V. Zacarias, E. A. Sippert, P Y. Tsuneto, J. E. L. Visentainer, C. D. O. E. Silva, and A. M. Sell, "The influence of interleukin 17A and IL17F polymorphisms on chronic periodontitis disease in Brazilian patients," Mediators of Inflammation, vol. 2015, Article ID 147056, 8 pages, 2015.

[16] X. Wu, Z. Zeng, B. Chen et al., "Association between polymorphisms in interleukin-17A and interleukin-17F genes and risks of gastric cancer," International Journal of Cancer, vol. 127, no. 1, pp. 86-92, 2010.

[17] L. Wang, Y. Jiang, Y. Zhang et al., "Association analysis of IL-17A and IL-17F polymorphisms in Chinese han women with breast cancer," PLoS ONE, vol. 7, no. 3, Article ID e34400, 2012.

[18] D. A. L. Rodriguez, L. E. Echeverria, C. I. Gonzalez, and J. Martin, "Investigation of the role of IL17A gene variants in Chagas disease," Genes and Immunity, vol. 16, no. 8, pp. 536540, 2015.

[19] O. P. Dutra, H. W. Besser, H. Tridapalli et al., "Sociedade Brasileira de Cardiologia, II Brazilian guideline for severe heart disease," Arquivos Brasileiros de Cardiologia, vol. 87, no. 2, pp. 223-232, 2006.

[20] F. C. Parra, R. C. Amado, J. R. Lambertucci, J. Rocha, C. M. Antunes, and S. D. J. Pena, "Color and genomic ancestry in Brazilians," Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 1, pp. 177-182, 2003.

[21] S. W. M. John, G. Weitzner, R. Rozen, and C. R. Scriver, "A rapid procedure for extracting genomic DNA from leukocytes," Nucleic Acids Research, vol. 19, no. 2, article 408, 1991.

[22] Sun Wei Guo and E. A. Thompson, "Performing the exact test of Hardy-Weinberg proportion for multiple alleles," Biometrics, vol. 48, no. 2, pp. 361-372, 1992.

[23] X. Sole, E. Guino, J. Valls, R. Iniesta, and V. Moreno, "SNPStats: a web tool for the analysis of association studies," Bioinformatics, vol. 22, no. 15, pp. 1928-1929, 2006.

[24] P. M. da Matta Guedes, F. R. S. Gutierrez, F. L. Maia et al., "IL17 produced during Trypanosoma cruzi infection plays a central role in regulatingparasite-induced myocarditis," PLoS-Neglected Tropical Diseases, vol. 4, no. 2, article e604, 2010.

[25] Y. Miyazaki, S. Hamano, S. Wang, Y. Shimanoe, Y. Iwakura, and H. Yoshida, "IL-17 is necessary for host protection against acutephase Trypanosoma cruzi infection," The Journal of Immunology, vol. 185, no. 2, pp. 1150-1157, 2010.

[26] L. M. D. Magalhaes, F. N. A. Villani, M. D. C. P. Nunes, K. J. Gollob, M. O. C. Rocha, and W. O. Dutra, "High interleukin 17 expression is correlated with better cardiac function in human Chagas disease," The Journal of Infectious Diseases, vol. 207, no. 4, pp. 661-665, 2013.

[27] Y. Peng, B. Zhou, Y.-Y. Wang et al., "Analysis of IL-17 gene polymorphisms in Chinese patients with dilated cardiomyopathy," Human Immunology, vol. 74, no. 5, pp. 635-639, 2013.

[28] A. Rassi Jr., A. Rassi, W. C. Little et al., "Development and validation of a risk score for predicting death in Chagas' heart disease," New England Journal of Medicine, vol. 355, no. 8, pp. 799-808, 2006.

[29] K. C. Fae, S. A. Drigo, E. Cunha-Neto et al., "HLA and [beta]-myosin heavy chain do not influence susceptibility to Chagas' disease cardiomyopathy," Microbes and Infection, vol. 2, no. 7, pp. 745-751, 2000.

Pamela Guimaraes Reis, (1) Christiane Maria Ayo, (2) Luiz Carlos de Mattos, (2) Cinara de Cassia Brandao de Mattos, (2) Karina Mayumi Sakita, (1) Amarilis Giaretta de Moraes, (1) Larissa Pires Muller, (3) Julimary Suematsu Aquino, (1) Luciana Conci Macedo, (1) Priscila Saamara Mazini, (1) Ana Maria Sell, (1,3) Divina Seila de Oliveira Marques, (4) Reinaldo Bulgarelli Bestetti, (5) and Jeane Eliete Laguila Visentainer (1,3)

(1) Post Graduation Program of Biosciences and Physiopathology, Department of Analysis Clinical and Biomedicine, Maringa State University, Maringa, PR, Brazil

(2) Laboratory of Immunogenetics, Department of Molecular Biology, Medical School, Sao Jose do Rio Preto, SP, Brazil

(3) Laboratory of Immunogenetics, Department of Basic Health Sciences, Maringa State University, Maringa, PR, Brazil

(4) Department of Medical Clinic, Londrina State University, Londrina, PR, Brazil

(5) Department of Cardiology and Cardiovascular Surgery, Medical School, Sao Jose do Rio Preto, SP, Brazil

Correspondence should be addressed to Jeane Eliete Laguila Visentainer;

Received 23 September 2016; Accepted 30 January 2017; Published 2 April 2017

Academic Editor: Margarete D. Bagatini
Table 1: Characteristics of the chronic Chagas disease patients
and controls from South and Southeast of Brazil.

                               CD patients              CCC
                                 N = 260              N = 212

Gender (a) n (%)
  Male                          121 (46.5)           97 (45.8)
  Female                        139 (53.5)           115 (54.2)
Age (b)
  Min-max                         31-90                31-90
  Mean [+ or -] SD (year)   62.9 [+ or -] 10.0   63.9 [+ or -] 10.2

                              Without CCC            Control
                                 N = 48              N = 150

Gender (a) n (%)
  Male                          24 (50.0)           74 (49.3)
  Female                        24 (50.0)           76 (50.7)
Age (b)
  Min-max                         38-76               28-100
  Mean [+ or -] SD (year)   58.6 [+ or -] 7.8   62.3 [+ or -] 17.4

CCC, patients with chronic Chagas cardiomyopathy; Min, minimum age;
Max, maximum age; SD, standard deviation.

(a) No statistically significant difference was observed between
the groups for gender.

(b) Statistically significant difference was observed between the
groups for age: CCC versus without CCC.

Table 2: Genotypes and allele frequencies distribution of IL17A
rs2275913 and IL17F rs763780 in Chagas disease patients and
controls in a population from South and Southeast of Brazil.

Allele/genotype    CD patients          CCC         Without LVSD
n (%)                N = 260          N = 212         N = 109

IL17A G197A
G                   369 (71.2)       297 (70.4)      159 (72.9)
A                 149 (28.8) (a)   125 (29.6) (b)    59 (27.1)
GG                  130 (50.2)       104 (49.3)      58 (53.2)
GA                  109 (42.1)       89 (42.2)       43 (39.5)
AA                 20 (7.7) (e)     18 (8.5) (f)       8 (73)

IL17F T7488C
T                   484 (93.1)       394 (92.9)      207 (94.9)
C                    36 (6.9)         30 (7.1)        11 (5.1)
TT                  224 (86.2)       182 (85.8)      98 (89.9)
TC                  36 (13.8)        30 (14.2)       11 (10.1)

Allele/genotype    With LVSD      Mild/moderate LVSD   Severe LVSD
n (%)                N = 103            N = 52            N = 51

IL17A G197A
G                  138 (67.6)         72 (70.6)          66 (64.7)
A                 66 (32.4) (c)       30 (29.4)        36 (35.3) (d)
GG                  46 (45.1)         24 (47.0)          22 (43.1)
GA                  46 (45.1)         24 (47.0)          22 (43.1)
AA                10 (9.8) (g)         3 (6.0)         7 (13.8) (h)

IL17F T7488C
T                   187(90.8)         97 (93.3)          90 (88.2)
C                   19 (9.2)           7 (6.7)           12 (11.8)
TT                  84 (81.6)         45 (86.5)          39 (76.5)
TC                  19 (18.4)          7 (13.5)          12 (23.5)

Allele/genotype   Without CCC    Control
n (%)               N = 48       N = 150

IL17A G197A
G                  72 (75.0)    235 (78.3)
A                  24 (25.0)    65 (21.7)
GG                 26 (54.2)    88 (58.7)
GA                 20 (41.7)    59 (39.3)
AA                  2 (4.1)      3 (2.0)

IL17F T7488C
T                  90 (93.7)    282 (94.0)
C                   6 (6.3)      18 (6.0)
TT                 42 (87.5)    132 (88.0)
TC                 6 (12.5)     18 (12.0)

CCC: patients with chronic Chagas cardiomyopathy; LVSD: left
ventricular systolic dysfunction; Recessive model: AA versus GA +

confidence interval. Adjustment of the genotypic differences for
the effect of age and gender was applied.

(a) P = 0.032. OR = 146 and 95% CI = 1.05-2.05; CD patients versus

(b) P = 0.021. OR = 1.52 and 95% CI = 1.08-2.15; CCC versus

(c) P = 0.009. OR = 1.73 and 95% CI = 1.15-2.59.With LVSD versus

(d) P = 0.009. OR = 1.97 and 95% CI = 1.20-3.21. Severe LVSD versus

(e) Recessive model: P = 0.009; OR = 4.12; 95% CI = 1.20-14.13. CD
patients versus controls.

(f) Recessive model: P = 0.005; OR = 4.67; 95% CI = 1.35-16.18. CCC
versus controls.

(g) Recessive model: P = 0.005; OR = 5.73; 95% CI = 1.52-21.64.
With LVSD versus controls.

(h) Recessive model: P = 0.002; OR = 8.18; 95% CI = 2.00-33.51.
Severe LVSD versus controls.

Table 3: Genotype frequencies of IL17A rs2275913 in Brazilian
patients with LVSD in chronic Chagas cardiomyopathy, stratified
according to gender.

Gender   IL17A G197A    With LVSD      Mild/moderate   Control
                           n (%)        LVSD n (%)      n (%)

             GG          23 (45.1)      13 (59.1)     43 (58.11)
Male         GA          24 (4706)       9 (40.9)     30 (40.54)
             AA          4 (7.84)           0          1 (1.35)
             GG          23 (45.1)      11 (37.93)    45 (59.21)
Female       GA         22 (43.14)      15 (51.72)    29 (38.16)
             AA        6 (11.76) (a)   3(10.35) (b)    2 (2.63)

LVSD, chronic Chagas cardiomyopathy patients with left ventricular
systolic dysfunction; OR, odds ratio; CI, confidence interval.
Data adjusted by age.

Only significant results are showed.

(a) OR = 6.63 and 95% CI = 1.21-36.40; with LVSD versus control.

(b) OR = 7.57 and 95% CI = 1.07-53.40; mild/moderate LVSD versus

Table 4: Genotype frequencies of IL17F rs753780 in Brazilian
Chagas disease patients with chronic cardiomyopathy, stratified
according to gender.

Gender   IL17F T7488C   Without LVSD    Mild/moderate   Severe LVSD
                            n (%)        LVSD n (%)        n (%)

Male          TT         40 (86.96)       21 (91.3)      19 (65.5)
              TC        6 (13.04) (a)    2 (8.7) (b)     10 (34.5)
Female        TT         58 (92.06)       24 (82.8)      20 (90.9)
              TC           5 (794)         5 (172)        2 (9.1)

Gender   IL17F T7488C    Without        Controls
                         CCC n (%)        n (%)

Male          TT         22 (45.8)      64 (86.49)
              TC        2 (4.2) (c)   10 (13.51) (d)
Female        TT         20 (41.7)      68 (89.47)
              TC          4 (8.3)       8 (10.53)

CCC, chronic Chagas cardiomyopathy; LVSD, left ventricular systolic
dysfunction; OR, odds ratio; CI, confidence interval. Data adjusted
by age.

Only significant results are showed.

(a) OR = 4.82 and 95% CI = 1.55-14.98; severe LVSD versus without

(b) OR = 6.02 and 95% CI = 1.18-30.78; severe LVSD versus
mild/moderate LVSD.

(c) OR = 6.70 and 95% CI = 1.19-37.53; severe LVSD versus without
CCC patients.

(d) OR = 3.40 and 95% CI = 1.24-9.31; severe LVSD versus controls.
COPYRIGHT 2017 Hindawi Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Research Article
Author:Reis, Pamela Guimaraes; Ayo, Christiane Maria; Mattos, Luiz Carlos de; Cassia Brandao de Mattos de,
Publication:Journal of Immunology Research
Article Type:Report
Geographic Code:3BRAZ
Date:Jan 1, 2017
Previous Article:Altered Intracellular ATP Production by Activated CD4+ T-Cells in Very Preterm Infants.
Next Article:Diagnostic and Research Aspects of Small Intestinal Disaccharidases in Coeliac Disease.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters